CAJ | 학술논문

目的：：观察伊马替尼治疗Ph+慢性粒细胞白血病的疗效。方法：将46例Ph+慢性粒细胞白血病患者随机分为2组，治疗组(29例)采用伊马替尼治疗，对照组(17例)采用干扰素-α、羟基脲治疗；并比较2组治疗后血液学缓解率和细胞遗传学缓解率。结果：治疗组完全血液学缓解率和主要细胞遗传学缓解率均高于对照组(p<0.05)，伊马替尼的不良反应轻微。结论：伊马替尼明显提高Ph+CML血液学缓解率和细胞遗传学缓解率，改善生活质量、延长无疾病进展生存期。
목적：：관찰이마체니치료Ph+만성립세포백혈병적료효。방법：장46례Ph+만성립세포백혈병환자수궤분위2조，치료조(29례)채용이마체니치료，대조조(17례)채용간우소-α、간기뇨치료；병비교2조치료후혈액학완해솔화세포유전학완해솔。결과：치료조완전혈액학완해솔화주요세포유전학완해솔균고우대조조(p<0.05)，이마체니적불량반응경미。결론：이마체니명현제고Ph+CML혈액학완해솔화세포유전학완해솔，개선생활질량、연장무질병진전생존기。
Objective:To observe the effect of imatinib on patients with Philadelphia chromosome-positive( Ph-positive) of chronic myeloid leukemia . Methods: Forty-six patients with Philadelphia chromosome-positive(Ph-positive) of chronic myeloid leukemia were rangomly divided into two groups,the treatment group (29 cases) and the control group (19 cases) Patients in the treatment group were treated with imatinib. the patients in the control group were treated with hydroxyurea(hu) ,interferon-α(IFN-α). The response rates of hematology and cytogene were compared after treatment. Results:The complete respse rate of hematology and the key response rate of cytogenge in the treatment group were higher than those in the control group (p<0. 05). Conclusion: Imainib significantly could im-prove hematology and cytogenetic response rates ,quality of life,and progression-free survival for patients with Ph-positive of chronic myeloid leukemia .